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ABSTRACT
Objective: This research was instigated to determine and assess the prevalence, severity, type, and the total number of potential drug interactions in 
the neurology department of two hospitals in India.
Methods: The data were collected from the prescriptions and by patient history interview on a daily basis. The drug-drug interactions (DDIs) were 
identified using Micromedex® database-2.7 and drugs.com.
Results: The drug interactions were influenced by a plethora of risk factors: Gender, age, comorbidities, length of hospital stay, and the neurological 
condition. The study was comprised 320 patients, among 196 patients were identified with potential DDIs (PDDIs), and a total of 450 PDDIs were 
observed. The prevalence of PDDIs according to the severity was major (42.6%), moderate (45.11%), and minor (12.22%).
Conclusion: To lessen PDDIs, the range of medications for the patients must be properly managed, and it is encouraged to remove all medicines 
without therapeutic advantage, intention, and an indication.
Keywords: Neurology, Drug-drug interactions, Risk factors.
INTRODUCTION
Drug-drug interactions (DDIs) are defined as two or more drugs 
interacting in such a manner that the effectiveness or toxicity of 
one or more drugs is altered [1,2]. DDIs are an important subgroup 
of adverse drug events (ADE) [3] which are highly prevalent in 
patients receiving multiple-drug treatment [4]. The majority of the 
interactions occur because either prescriber’s do not consider them 
relevant [5,6] or prescriber may be receiving less information in the 
DDIs area. Polypharmacy, geriatric, and patients with comorbidities 
are considered as one of the major risk factors in the precipitation of 
DDIs [5]. Neurological illnesses are one among the most common causes 
of hospitalization. It is estimated that DDIs account for approximately 
2.8% of hospital admission every year [6].
The issue of drug interactions is a global concern; a study of the US 
reported that 30.3% of patients are at the risk of DDIs [7]. A recent study 
in Iran has reported that in 35.5% of the patients in the neurology ward 
encountered with at least one potential DDIs (PDDIs) [8]. The burden of 
neurological disorders in India is estimated over 30 million which often 
warrant complex therapeutic regimen [9]. In India, a study identified 
66% of DDIs in a medical department of a tertiary care hospital in 
Karnataka, India [10], while another study in Chandigarh reported that 
8.3% prescriptions had multiple DDIs [11]. It was estimated that about 
46.3% of drug interactions were seen in neurological patients in a cross-
sectional study conducted in Karnataka and the majority of the DDIs 
were moderate in severity and required therapeutic monitoring [12].
An exhaustive literature search did not reveal as many published 
reports on DDIs in neurological disorders in Indian population or other 
countries; however, similar studies in other hospital wards have been 
done. The present study was instigated to determine the prevalence and 
assessment of DDIs in patients admitted to the neurology department 
and to identify PDDIs risk factors. In view of above-mentioned statistics, 
we purposefully conducted this study in a tertiary care hospital in Erode 
as there are no studies targeted this region of the country.
METHODS
The research was a prospective observational study; the work was 
reviewed and approved by the Institute Ethics Committee (Human 
Studies), ethics number is JKKNCP/ETHICS_PRACTICE/017PDS05. 
It was conducted at a tertiary care hospital, Erode, Tamil Nadu, 
India. The study period was 6 months, with a sample size 320 
inpatients. The inclusion criteria were patients with neurological 
disorders. Both gender of patients, along with 12 years of age with 
co-morbidities. The prospective study was carried out for a period 
of 6 months in the neurology department of a tertiary care hospital, 
Erode.
RESULTS
A total of 320 inpatients were selected from a neurological department 
in tertiary care hospitals. It includes the cases of Stroke, Epilepsy, 
Parkinson’s disease, Alzheimer’s disease, and its comorbidities. A total 
number of cases have interaction; drug-drug (196), drug-food (90), and 
drug-disease (166) and the total number of interactions; drug-drug 
(450), drug-food (105), and drug-disease (263), respectively (Fig. 1).
In this study, we mainly focused on DDIs. Demographic details of the 
same are given Tables 1 and 2.
PDDI in males (108) and females (88) shows that most interactions 
are found in stroke (39.79%) and least among Alzheimer’s disease 
(2.04%). Another study [13] reported out of 200 patients, ischemic 
stroke patients were higher than hemorrhagic stroke.
The most common interacting pair was found to be aspirin+clopidogrel-
major with a frequency of 67, and the least was found to be 
amitriptylline+fluoxetine-major (Table 3).
The total number of PDDI and prevalence for 196 out of 320 patients 
was found to be 450 PDDIs and 42.66%, respectively (Table 4).
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There were 72 interacting pairs identified during the study. Among 
450 PDDIs, 268 (59.55%) were pharmacokinetic (PK) interactions, 
140 (31.13%) were pharmacodynamic (PD) interactions, 8 (1.77%) 
were of both PK+PD interactions, and 34 (7.55%) were unknown 
interactions (Fig. 2).
Among 268 PK DDIs, 228 (85.07%) were due to metabolism, 10 (3.75%) 
were due to absorption, 7 (2.61%) were due to distribution, 2 (0.74%) 
were due to excretion, and 21 (7.83%) were due to both distribution + 
excretion interactions (Fig. 3).
Among 140 PD DDIs, 75 (53.57%) were additive, 48 (32.28%) were 
antagonistic, and 17 (12.14%) were synergistic interactions (Fig. 4).
DISCUSSION
In our study, the male population shown more drug interactions than 
the female population, it may be due to the fact that more hospital 
admissions were seen in male patients. Similar results were obtained 
in a study [14], and they state it is due to the early detection of common 
Fig. 4: Type of pharmacodynamics interaction
Fig. 3: Type of pharmacokinetic interaction
Fig. 2: Types of potential drug-drug interactions
Fig. 1: Distribution of the total number of potential drug 
interactions
















Table 2: Gender-wise distribution of PDDIs






Stroke 40 38 78 (39.79)
Stroke+Alzheimer’s disease 6 3 9 (4.59)
Stroke+Parkinson’s disease 3 5 8 (4.08)
Stroke+Epilepsy 11 10 21 (10.71)
Epilepsy 36 21 57 (29.10)
Parkinson’s disease 9 6 15 (7.65)
Alzheimer’s disease 1 3 4 (2.04)
Others 2 2 4 (2.04)
PDDIs: Potential drug-drug interactions
Table 3: Highest PDDI combinations in neurology
PDDI combination Type Severity Frequency 
n=450 (%)
Aspirin+clopidogrel PD Major 67 (14.88)
Carbamazepine+phenytoin PK Major 22 (4.88)
Aspirin+metformin PD Major 10 (2.22)
Amlodipine+clopidogrel PK Major 9 (2)
Atorvastatin+clopidogrel PK Moderate 40 (8.88)
Clonazepam+theophylline PD Moderate 9 (2)
Phenytoin+clonazepam PK Moderate 7 (1.55)
Clobazam+carbamazepine PK Minor 22 (4.88)
Amitriptyline+fluoxetine PK+PD Major 5 (1.11)
Diazepam+phenytoin Unknown Major 21 (4.66)
PDDI: Potential drug-drug interaction
Table 4: Prevalence of PDDIs




PDDIs: Potential drug-drug interactions
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disorders in male patients. However, another study [15] shows that 
the female population was found with more drug interactions because 
in their study center more number of female patients were diagnosed 
with more diseases than males. The study shows that more commonly 
occurring neurological disorder is a stroke; hypertension is the leading 
cause of stroke, smoking habit in male patients enhances the risk of 
stroke in male patients, which is similar to the study [16].
According to our study, most of the patients were of age group between 
60 and 70 years. As people get aged, the amount of water in the body 
decreases as well as the amount of fat tissue relative to water increases. 
Furthermore, the kidney efficiency to excrete drugs through urine 
and metabolism by the liver get decreased. A study [14] reported that 
the majority of patients were aged above 51 years and were followed 
by other age groups, whereas, a study [17] reported an age group of 
60–70 years. Older people are at high risk of developing an ADR due to 
PDDI for several reasons.
The study reveals that 56.25% of cases reported are having a hospital 
stay of 4–6 days. In another study [18] which showed that the majority 
of the cases, the number of hospital stay was more than 7 days. The 
likelihood of getting the multiple drugs increases with the increased 
length of hospital stay which, in turn, will increase the likelihood 
of PDDIs. Another study [19] revealed that 380 (72.53%) cardiac, 
275 (64.70%) neurology of patients and reported that the number of 
days hospital stay was between 4 and 6 days.
In our study, 41.9% cases have more than 7 drugs prescribed in 
the neurology department; whereas 62% cases were reported to 
be prescribed with more than 8 medications in the study which was 
conducted [20] in the neurology department [21]. The concurrent use 
of three or more drugs increases the risk of ADE’s by 9.8 times; they 
stated that more the number of medications prescribed, the more the 
possibility of irrational polypharmacy. In our study, we found that male 
patients were higher in number when compared to female patients, 
which were similar to the study [8]. Another study [14] which also 
reported that male patients were higher (70.4%) when compared to 
female patients. The most common interacting pair was found to be 
aspirin-clopidogrel; which is a major PD interaction, with a frequency 
of 67. This interacting pair increases the risk of bleeding due to their 
additive effects which are managed by monitoring of blood counts. 
This is similar to the study [22] in which most common interacting pair 
was identified as aspirin-clopidogrel. Another study [8] which is quite 
different from this study; clopidogrel-omeprazole was identified as the 
most common interacting pair.
The highest percentage of PDDI; in stroke (aspirin + clopidogrel) 
is 24.78%, in epilepsy (carbamazepine + phenytoin and clobazam 
+ carbamazepine) is 9.32%, in Parkinson’s disease (clonazepam + 
theophylline) is 2.50%, and in Alzheimer’s disease is 22.72%. The 
total number of PDDI and the prevalence of 196, out of 320 patients, 
were found to be 450 and 61.25%, respectively. A similar study [23] 
in the department of neurology showed that the prevalence rate of 
PDDI was 71.6% among the patients. In our study, the prevalence of 
PDDIs was more in moderate severity (45.11%). Similarly, Lubinga 
and Uwiduhaye [12] reported 72% PDDIs were moderate severity, 
and 20% were observed to be major in severity. Another study [24] 
reported that 35% is of major severity, which is contrasted with 
the other studies. Out of 320 cases, there were 72 interacting pairs 
identified during the study. Among 450 PDDIs, 268 (59.55%) were 
due to PK interactions, 140 (31.13%) were due to PD interactions, 
8 (1.77%) showing both PK and PD, and 34 (7.55%) were of unknown 
mechanism.
Among 268 PK DDIs, 228 (85.07%) were due to metabolism, which is in 
contrast with a study [24] where the majority of interactions were due 
to absorption. Among 140 PD DDIs, 75 (53.57%) were due to additive 
effects which are in contrast with the study [25] where 67.44% were 
synergistically followed by 30.7% antagonistic.
CONCLUSION
Our study concluded that the overall incidence of PDDIs was very high 
in the neurology department. It was found that the incidence of PDDIs 
was associated with older age, male gender, number of medication 
given and increased lengths of hospital stay. To reduce PDDIs, the 
number of medications for the patients should be properly controlled, 
and it is recommended to eliminate all medications without therapeutic 
benefit, the goal and indication.
Pharmacists must take responsibility for monitoring drug interactions 
and notifying the physician and patient about potential problems. After 
completion of the study, it was observed that there was an alarming 
rate of DDIs. Knowledge of such predictable or possible interactions 
is necessary for their timely detection and prevention of associated 
morbidity.
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